biote (BTMD) Projected to Post Earnings on Wednesday

Key Points

• biote (NASDAQ: BTMD) is expected to release its Q2 2025 earnings on August 6th, with analysts forecasting earnings of $0.06 per share and revenue of $49.52 million.
• As of the latest trading session, biote shares were down 2.6% to $4.43, with a market capitalization of $242.37 million.
• Major shareholder Guines LLC increased their stake by purchasing 436,037 shares at an average cost of $3.26 per share, boosting their total ownership to over 4.6 million shares.

biote (NASDAQ:BTMD - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect biote to post earnings of $0.06 per share and revenue of $49.52 million for the quarter. biote has set its FY 2025 guidance at EPS.

biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. biote had a negative return on equity of 19.44% and a net margin of 10.93%. The business had revenue of $48.99 million for the quarter, compared to analyst estimates of $47.25 million. On average, analysts expect biote to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Trading Down 4.4%

Shares of NASDAQ:BTMD traded down $0.18 during midday trading on Friday, hitting $3.89. The company had a trading volume of 120,114 shares, compared to its average volume of 84,602. biote has a 12 month low of $3.04 and a 12 month high of $7.34. The stock has a market cap of $212.82 million, a price-to-earnings ratio of 6.38 and a beta of 1.21. The firm has a fifty day simple moving average of $4.01 and a 200 day simple moving average of $4.11.

Insiders Place Their Bets

In other biote news, major shareholder Guines Llc bought 436,037 shares of biote stock in a transaction on Tuesday, May 6th. The shares were purchased at an average cost of $3.26 per share, for a total transaction of $1,421,480.62. Following the completion of the acquisition, the insider owned 4,611,071 shares in the company, valued at approximately $15,032,091.46. The trade was a 10.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 24.00% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in biote stock. AQR Capital Management LLC bought a new position in shares of biote Corp. (NASDAQ:BTMD - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 12,871 shares of the company's stock, valued at approximately $43,000. Institutional investors and hedge funds own 21.68% of the company's stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.